Dong-A ST Co., Ltd. (170900.KS)
KRW 47300.0
(-1.77%)
KRW 47300.0
(-1.77%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 11.17 Billion KRW | -32.95% |
| 2022 | 16.67 Billion KRW | -22.19% |
| 2021 | 21.42 Billion KRW | -36.96% |
| 2020 | 33.99 Billion KRW | -66.34% |
| 2019 | 100.98 Billion KRW | 156.09% |
| 2018 | 39.43 Billion KRW | 65.22% |
| 2017 | 23.86 Billion KRW | 60.81% |
| 2016 | 14.84 Billion KRW | -73.2% |
| 2015 | 55.38 Billion KRW | 12.19% |
| 2014 | 49.36 Billion KRW | 24.08% |
| 2013 | 39.78 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -16.09 Billion KRW | -285.47% |
| 2024 Q2 | -5.98 Billion KRW | 62.82% |
| 2023 Q2 | 3.43 Billion KRW | -15.26% |
| 2023 Q3 | 7.86 Billion KRW | 128.74% |
| 2023 Q1 | 4.05 Billion KRW | 365.93% |
| 2023 Q4 | -4.17 Billion KRW | -153.12% |
| 2023 FY | 11.17 Billion KRW | -32.95% |
| 2022 Q4 | -1.52 Billion KRW | -110.44% |
| 2022 Q2 | 4.38 Billion KRW | -94.28% |
| 2022 Q1 | 76.71 Billion KRW | 1704.84% |
| 2022 FY | 16.67 Billion KRW | -22.19% |
| 2022 Q3 | 14.6 Billion KRW | 232.76% |
| 2021 Q1 | 879.53 Million KRW | 105.38% |
| 2021 Q3 | 11.61 Billion KRW | 46.8% |
| 2021 Q4 | -4.78 Billion KRW | -141.17% |
| 2021 FY | 21.42 Billion KRW | -36.96% |
| 2021 Q2 | 7.9 Billion KRW | 799.26% |
| 2020 Q3 | 6.75 Billion KRW | 171.64% |
| 2020 FY | 33.99 Billion KRW | -66.34% |
| 2020 Q2 | -9.43 Billion KRW | -117.8% |
| 2020 Q1 | 53 Billion KRW | 989.75% |
| 2020 Q4 | -16.33 Billion KRW | -341.71% |
| 2019 FY | 100.98 Billion KRW | 156.09% |
| 2019 Q4 | 4.86 Billion KRW | -77.25% |
| 2019 Q3 | 21.38 Billion KRW | 116.44% |
| 2019 Q2 | 9.87 Billion KRW | -51.65% |
| 2019 Q1 | 20.43 Billion KRW | 2981.22% |
| 2018 Q2 | 20.25 Billion KRW | 92.35% |
| 2018 FY | 39.43 Billion KRW | 65.22% |
| 2018 Q3 | 7.98 Billion KRW | -60.61% |
| 2018 Q4 | 663.2 Million KRW | -91.69% |
| 2018 Q1 | 10.53 Billion KRW | 2160.21% |
| 2017 Q2 | 3.71 Billion KRW | -22.4% |
| 2017 Q1 | 4.79 Billion KRW | 173.38% |
| 2017 Q3 | 15.86 Billion KRW | 326.72% |
| 2017 FY | 23.86 Billion KRW | 60.81% |
| 2017 Q4 | -511.23 Million KRW | -103.22% |
| 2016 Q4 | -6.53 Billion KRW | -507.41% |
| 2016 FY | 14.84 Billion KRW | -73.2% |
| 2016 Q1 | 12.08 Billion KRW | 15.62% |
| 2016 Q2 | 9.19 Billion KRW | -23.97% |
| 2016 Q3 | 1.6 Billion KRW | -82.56% |
| 2015 FY | 55.38 Billion KRW | 12.19% |
| 2015 Q3 | 16.05 Billion KRW | 1.1% |
| 2015 Q2 | 15.87 Billion KRW | 22.15% |
| 2015 Q1 | 13 Billion KRW | 3.53% |
| 2015 Q4 | 10.45 Billion KRW | -34.88% |
| 2014 Q1 | 11.55 Billion KRW | 5.17% |
| 2014 Q2 | 11.39 Billion KRW | -1.39% |
| 2014 Q3 | 13.85 Billion KRW | 21.61% |
| 2014 Q4 | 12.55 Billion KRW | -9.4% |
| 2014 FY | 49.36 Billion KRW | 24.08% |
| 2013 Q2 | 10.09 Billion KRW | 162.41% |
| 2013 FY | 39.78 Billion KRW | 0.0% |
| 2013 Q1 | 3.84 Billion KRW | 0.0% |
| 2013 Q3 | 14.85 Billion KRW | 47.2% |
| 2013 Q4 | 10.98 Billion KRW | -26.04% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -2966.481% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 85.46% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 22.104% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 120.927% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 114.05% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 58.646% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 661.974% |
| Yuhan Corporation | 74.56 Billion KRW | 85.008% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 161.956% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -265.78% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -1774.314% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -1059.874% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | 45.429% |
| CKD Bio Corp. | -20.15 Billion KRW | 155.469% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -2966.481% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -177.132% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 115.981% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 88.855% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 123.587% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -61.377% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -258.584% |
| HANDOK Inc. | 12.57 Billion KRW | 11.133% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -2966.481% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 77.078% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 91.621% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 88.855% |
| Yuhan Corporation | 74.56 Billion KRW | 85.008% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 46.566% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 95.029% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 95.467% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 74.001% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 88.855% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 66.276% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 244.126% |
| JW Holdings Corporation | 143.66 Billion KRW | 92.219% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -72.746% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -28.026% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 123.587% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 65.32% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 79.657% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 65.631% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 55.82% |
| Boryung Corporation | 68.26 Billion KRW | 83.625% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 129.812% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 22.104% |
| JW Lifescience Corporation | 32.09 Billion KRW | 65.167% |